Health ❯ Healthcare ❯ Pharmaceuticals

Drug Regulation

FDA FDA Actions Mifepristone FDA Decisions Counterfeit Drugs GLP-1 Drugs Compounding Pharmacies FDA Oversight Quality Control Anvisa

Regulators Move to Strip Approval of Tavneos After Trial Misconduct and Liver Safety Signals

The move could remove Tavneos from markets, upend care for current patients, increase scrutiny of clinical trial oversight.

EMA Committee Recommends Revoking Tavneos Authorization

India Bans 16 Fixed‑Dose Combination Drugs

Pakistan Approves Nationwide Digital Track-and-Trace System for Medicines

Anvisa Suspends Enalapril and Halaven Lots After Manufacturers Report Quality and Labeling Faults

Rajasthan Bans TOCIN Oxytocin After Sample Shows No Active Ingredient

India Reclassifies Pregabalin as Schedule H1

Anvisa Halts Specific Lots of Cimed Statins and Hypofarma Dexamethasone

Kissei Discloses 20 Deaths in Japan Among Tabneous Users

FDA Names Mike Davis Acting Drug Chief as Tracy Beth Høeg Exits

Kissei Tells Japan Doctors to Halt New Tavneos Use After 20 Deaths Reported

FDA Proposes Blocking Bulk Compounding of GLP-1 Drugs by Outsourcing Facilities

NCB Launches Operation WIPE to Target Illegal Online Sales of NDPS Drugs

Argentina Bill Seeks Tighter Propofol Controls After Hospital Diversion Cases

Telangana Drug Regulator Flags 75 Pharmacies in GLP-1 Sales Crackdown

ANMAT Suspends Global Pharma Group Over Cold-Chain and Traceability Failures

Gurugram Bust Seizes 242 Suspected Fake Mounjaro Pens, Two Arrested

Anvisa Seizes Suspect Mounjaro Lots, Bans Unregistered Tirzec in Brazil

Telangana Regulator Warns Against Unsupervised Semaglutide Use

India Tightens Oversight as Low‑Cost Semaglutide Hits Pharmacies